The Distinguished Achievement Award is given to an individual in honor of his or her sustained scientific contributions to the field of liver disease and the scientific foundations of hepatology. The award honors a sustained contribution rather than a single discovery or major achievement.
Distinguished Chair Professor, Department of Pediatrics, at the National Taiwan University College of Medicine.
Over the span of 30 years, Dr. Chang’s team has provided the first and most long-term research on the effects of a cancer prevention vaccine in humans. The universal hepatitis B virus vaccination program for infants was launched in Taiwan in 1984, and since that time, the nationwide program has reduced the liver cancer incidence ratio from 1.00 to 0.25 in children and young adults. Her innovative universal screening method for biliary atresia, a life-threatening liver disease in newborns, was established in Taiwan in 2004 and has since been used in many countries. It has solidified the early diagnosis and treatment and greatly improved outcomes. Dr. Chang has also been an author/editor on more than 400 publications and served as president of the Federation of International Societies of Pediatric Gastroenterology, Hepatology and Nutrition from 2008 to 2012.
The Distinguished Clinician Educator/Mentor Award is given in honor of the sustained service of clinician educators to AASLD or the liver community in general. The award recognizes the skills of outstanding clinicians and educators who have made momentous contributions to hepatology over an extended period.
Clinical Hepatologist, Medical, and Research Director at the Liver Disease and Viral Hepatitis Program at Alaska Native Medical Center
Brian McMahon has directed the vaccination programs in Alaska that have reduced the rates of acute hepatitis A and B from the highest in the United States to the lowest in the world. He has been active in research in viral hepatitis A, B, and C, as well as other liver diseases among Alaska Native/American Indians for over 30 years. Dr. McMahon co-authored the AASLD Practice Guideline on Chronic Hepatitis B from 2001 to 2009 and additional contributions include serving on the methodology committee for the 2016 AASLD Guidelines and on the writing committee for the 2017 AASLD supplemental Guideline. He also held the position of co-chair of the WHO hepatitis B Guidelines Committee. During his career, Dr. McMahon has been the author of more than 120 peer-reviewed papers, 50 book chapters, review articles and editorials.
The Distinguished Service Award is given to an individual in honor of his or her sustained service to AASLD or the liver disease community in general. The award recognizes service provided to the community of hepatology researchers and clinicians over an extended period; service that is well above and beyond that provided by many members who serve on the Governing Board and Committees of AASLD.
John Senior became a member of the American Association for the Study of Liver Diseases in 1959 and was elected to the AASLD Council in 1969. In 1973, he became AASLD’s 25th President and continued to serve on the Governing Board until 1979. Dr. Senior, along with his immediate successor, Dr. Bill Summerskill, was instrumental in persuading the Board to take innovative steps to begin the series of annual courses in 1974; start a lay foundation, The American Liver Foundation in 1976; and start a new journal, HEPATOLOGY, in 1981. In June of 1995, he joined the Center for Drug Evaluation and Research, Food and Drug Administration (FDA) and serves today as a principal consultant in hepatology at the agency, focusing on preventing serious drug-induced liver injury. In 1999, Dr. Senior began organizing the series of annual, international conferences on drug-induced liver injury and continues to be active in that role with AASLD to this day.